Company intelligence
Inventiva Pharma
A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies.
About Inventiva Pharma
At Inventiva, we are united in developing differentiated treatments for MASH and making a meaningful difference in the lives of those affected. Recognizing that MASH is not just a liver disease but also a cardiometabolic condition, we have purposefully designed a potential oral therapy — currently in clinical development — intended to restore metabolic balance at the source and directly target inflammation and fibrosis. Our goal is to bring relief to patients across the MASH patient population, addressing a critical unmet need in a progressive and life-threatening disease. Our product candidate, lanifibranor, has been granted FDA Breakthrough Therapy Designation and is now being evaluated in a global Phase 3 clinical trial.
Verified activity
Signals from Inventiva Pharma
4 published signals
Presence & Recognition
Inventiva Pharma is attending the Paris MASH Meeting at Institut Pasteur on September 10-11 to showcase research through five preclinical and Phase 1/Phase 2 clinical abstracts and present during the Industry Corner on Friday, September 11, 2026.
Reported by Inventiva Pharma
Research & Knowledge
Inventiva Pharma announced that the last patient in the Phase 3 NATiV3 trial for MASH and moderate-to-advanced fibrosis has completed their 72-week treatment period.
Reported by Inventiva Pharma
People
Inventiva Pharma welcomed Chris Benecchi as Chief Operating Officer.
Reported by Inventiva Pharma
Capital & Finance
Inventiva Pharma is advancing toward anticipated topline results from the pivotal NATiV3 Phase 3 study of lanifibranor in Q4 of this year.
Reported by Inventiva Pharma